Company intelligence / Profile preview
Trutino Biosciences
San Diego, California, United Statestrutinobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead asset ODC‑IL2/TB‑055 has demonstrated preclinical proof-of-concept with tumor-localized activation of immune response and reduced systemic toxicity. IND approval secured; first-in-human studies planned for late 2024/early 2025.[1][6] No published clinical results yet.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Cytokines (engineered/conditional pro-cytokines)Large molecules[6][7][8]Fc-fusion proteins and antibodies mentioned as expertise area[9]
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Boehringer Ingelheim—option-to-acquire agreement and ongoing research partnership focused on immuno-oncology/cytokine therapies.[3]
Beyond the preview
Go deeper on Trutino Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trutino Biosciences.